Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers

被引:2
|
作者
Karim, Frederic [1 ]
Amin, Adina [1 ]
Liu, Marie [1 ]
Vishnuvardhan, Nivetha [2 ]
Amin, Saif [1 ]
Shabbir, Raffey [1 ]
Swed, Brandon [3 ]
Khan, Uqba [3 ]
机构
[1] New York Presbyterian Brooklyn Methodist Hosp, Internal Med, 506 6th St, Brooklyn, NY 11215 USA
[2] New York Presbyterian Brooklyn Methodist Hosp, Pediat Hematol Oncol, 506 6th St, Brooklyn, NY 11215 USA
[3] Weill Cornell Med, Hematol Oncol, 515 6th St, Brooklyn, NY 11215 USA
关键词
checkpoint inhibitors; esophageal cancer; gastric cancer; immunotherapy; PD-L1; HER2; clinical trials; HELICOBACTER-PYLORI INFECTION; ESOPHAGEAL CANCER; PLUS CHEMOTHERAPY; GASTRIC-CANCER; BARRETTS-ESOPHAGUS; 1ST-LINE TREATMENT; DOUBLE-BLIND; NIVOLUMAB; JUNCTION; HER2;
D O I
10.3390/cancers15164099
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This article reviews the essential clinical trials that have led to these immunother-apy approvals and explores the use of predictive biomarkers, such as PD-L1 expression and MSI status, to identify patients who are most likely to benefit from immunotherapies. Methods: This case review series describe findings from different clinical trials and contribute to the evolving understanding of the role of CPIs in managing advanced gastroesophageal cancers and may lead to improved treatment options and patient outcomes. Ongoing clinical trials also hold promise for expanding treatment options and improving patient outcomes in the future. Methods: The systematic review followed the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The protocol has not been registered. A systematic literature review was conducted to identify relevant clinical trials and studies that describe the role of immune checkpoint inhibitors in managing advanced gastroesophageal cancers. Electronic database (PubMed, Clinicaltri-als.gov, Society of Immunotherapy of Cancer, Aliment Pharmacology & Therapeutics, BMC cancer, Molecular Cancer Research, Nature Reviews Molecular Cell Biology, American Association for Cancer Research, Science, Nature, Cancer Discovery, Journal of the National Cancer Institute, Advanced Immunology, Oncotarget, Nature Medicine, Nature Genetics, Gut, Pathology and Oncology Research, Journal of Clinical Oncology, The New England Journal of Medicine, Gastrointestinal oncology, JAMA Oncology, Journal of Gastrointestinal Oncology, Current Oncology, Annals of Oncology, The Lancet, JCO Oncology Practice, Future Oncology, Gastric Cancer, CA: A Cancer Journal for Clinicians, American Journal of Gastroenterology, Gastroenterology, Journal of the National Cancer Institute, International Journal of Epidemiology, Helicobacter, Gastroenterology Review) were searched using a combination of relevant keywords and MESH terms. The search encompassed articles published up to 5/2023. Additionally, manual searches of reference lists of selected articles and pertinent review papers were conducted to ensure comprehensive coverage of relevant studies. Studies were included if they provided insights into clinical trials evaluating the efficacy and safety of CPIs in
引用
收藏
页数:18
相关论文
共 50 条
  • [31] The Role of Checkpoint Inhibitors in Glioblastoma
    Desai, Kunal
    Hubben, Anne
    Ahluwalia, Manmeet
    [J]. TARGETED ONCOLOGY, 2019, 14 (04) : 375 - 394
  • [32] Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers
    Meng Li
    Denis Kaili
    Lei Shi
    [J]. World Journal of Gastrointestinal Oncology, 2022, 14 (01) : 19 - 37
  • [33] Checkpoint inhibitors in bladder and renal cancers: results and perspectives
    Aoun, Fouad
    Kourie, Hampig R.
    Sideris, Spyridon
    Roumeguere, Thierry
    van Velthoven, Roland
    Gil, Thierry
    [J]. IMMUNOTHERAPY, 2015, 7 (12) : 1259 - 1271
  • [34] Responsiveness to immune checkpoint inhibitors in RET dependent cancers
    Hegde, Aparna
    Huang, Le
    Liu, Shuang
    Hess, Kenneth
    Cabanillas, Maria
    Hu, Mimi
    Busaidy, Naifa
    Sherman, Steven
    Simon, George
    Blumenschein, George
    Papadimitrakopoulou, Vassiliki A.
    Hong, David S.
    Meric-Bernstam, Funda
    Heymach, John
    Subbiah, Vivek
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [35] Immune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate?
    Jaing, Tang-Her
    Wang, Yi-Lun
    Chiu, Chia-Chi
    [J]. PHARMACEUTICALS, 2024, 17 (08)
  • [36] Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers
    Li, Meng
    Kaili, Denis
    Shi, Lei
    [J]. WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 14 (01) : 19 - 37
  • [37] Treatment of advanced urogenital cancers with immune checkpoint inhibitors
    Jung, Eun Hee
    Kim, Se Hyun
    [J]. JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2021, 64 (05): : 349 - 357
  • [38] Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
    Shen, Pan
    Han, Liang
    Ba, Xin
    Qin, Kai
    Tu, Shenghao
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [39] Safety of checkpoint inhibitors in older patients with genitourinary cancers
    Ramnaraign, Brian Hemendra
    Patel, Neil Jigish
    Chatzkel, Jonathan Alexander
    Hitchcock, Kathryn
    Zlotecki, Robert
    O'Malley, Padraic
    Crispen, Paul
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Immune checkpoint inhibitors in patients with cancers of unknown primary
    Rassy, Elie
    Karam, Elias
    Adeleke, Sola
    Okoli, Somto
    Galante, Joao
    Boussios, Stergios
    Pavlidis, Nicholas
    [J]. EUROPEAN JOURNAL OF CANCER, 2023, 195